Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
liposomal mitoxantrone hydrochloride + albumin-bound paclitaxel
- Development stage
- Unknown
- Lead developer
- CSPC Pharmaceutical Group
- Modality
- Small Molecules, Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
**Liposomal mitoxantrone hydrochloride + albumin-bound paclitaxel** is a combination of two chemotherapeutic agents formulated for improved pharmacokinetics and tolerability. Mitoxantrone hydrochloride is encapsulated in liposomes, a nanoparticle delivery system that enhances tumor targeting and reduces toxicity, while paclitaxel is bound to albumin nanoparticles, allowing solvent-free administration and improved tumor penetration. Mitoxantrone inhibits DNA topoisomerase II, blocking cell division and inducing immunogenic cell death; albumin-bound paclitaxel stabilizes microtubules, preventing mitosis and promoting apoptosis. This combination leverages both drugs' synergistic antineoplastic effects, and both liposomal and albumin-bound formulations are designed to maximize anti-tumor activity while minimizing adverse effects. Clinical use is primarily for refractory or advanced solid tumors and hematological malignancies[2][3][4][5].
- Other names
- mitoxantrone hydrochloride liposome + albumin-bound paclitaxel
02
Targets
TOP2A (DNA topoisomerase II)DNAMicrotubule
Beyond the preview
Go deeper on liposomal mitoxantrone hydrochloride + albumin-bound paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on liposomal mitoxantrone hydrochloride + albumin-bound paclitaxel.